Cell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted

By Reuters News


Overview

  • Cell-engineering firm's preliminary Q3 revenue rose 26% yr/yr, beating analyst expectations

  • Company raised full-year 2026 revenue guidance to about $34 mln

  • Q3 results driven by accelerated instrument purchasing from a large customer


Outlook

  • MaxCyte raises 2026 revenue guidance to about $34 mln from $30-32 mln

  • Company expects 2026 core business revenue of about $28 mln, up from $25-27 mln prior guidance

  • MaxCyte sees 2026 SPL Program-related revenue at about $6 mln, up from $5 mln prior view


Result Drivers

  • ACCELERATED PURCHASING - Co said Q3 results were driven by accelerated instrument purchasing from a large customer

  • MILESTONE REVENUE - Co recognized milestone revenue from SPL partner in Q3, its second milestone achieved in 2026


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$8.10 mln

$7.05 mln (5 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 366.7% above its October 13 closing price of $0.96


Reuters Recommended Reads

  • Oct 12 - Nurix Therapeutics Q3 swings to profit on Roche collaboration


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.